Intersect ENT is developing products to help us all breathe a lot easier. The commercial stage drug-device company caters to patients with ear, nose, and throat (ENT) conditions. Its drug-eluting bioabsorbable implant technology enables a targeted release of therapeutic agents that hold open a surgically enlarged sinus and gradually release an anti-inflammatory steroid over a period of 30 days and are absorbed into the body. Its initial products, PROPEL and PROPEL mini, have been approved by the FDA for use in patients with chronic sinusitis. In mid-2014, Intersect ENT launched an IPO.